You are now leaving Kedrion Corporate site. Medical information including licensed uses may be different outside of the EU countries.
NO
YES
About Kedrion - Front Image

Investor Relations

A 659.3  million euro’s turnover with a 15.6% rise on 2015, a 106.3 million of Euros adjusted EBITDA, a net profit of 11.8 million Euros: here are the key figures of 2016’s consolidated financial statement of accounts for Kedrion SpA, approved on 27th April 2017 by the Shareholders’ Meeting.

The Company has consolidated its position on the international markets thanks to an integrated business model that - to date - allows it to operate commercially in approximately 100 countries worldwide. The United States, in particular, are Kedrion’s main market, representing 45% of its total sales, whilst the Company continues to grow in other strategic markets.

News

Kedrion and Cerus enter distribution agreement for INTERCEPT in Italy

Agreement covers complete INTERCEPT product line: platelets, plasma, and red blood cells

read more 

Kedrion Biopharma and Kamada Ltd Receive FDA Approval for KEDRAB®

The product is approved for post-exposure prophylaxis against rabies infection

read more 

First half results 2017

First half consolidated turnover of EUR 271.7 M and adjusted EBITDA increase by 29.0% compared to the same period in 2016, with a margin of 24.1%

read more 

Financial information

About Kedrion - Front Image

    First Half Results 2017

    Financial Statements 2016

    Kedrion SpA Consolidated Financial Statements 2016

    Kedrion SpA Consolidated Financial Statements 2015

    Kedrion SpA Consolidated Financial Statements 2014

KEDRION NOTES

Maturity 24th April 2019 - XS1061608300

On April 16th 2014, Kedrion Group S.p.A. successfully completed the issuance of 300 million euro senior, unsecured and unrated notes, which will be due April 2019. They are fixed-rate securities with a 4.625% coupon p.a.. Issue price is at par (100%). With a minimum denomination of 100,000 euros, such notes have been placed with leading international institutional investors and have been listed on the Irish Stock Exchange by the date of accrual, April 24th 2014.

Maturity 12th July 2022 - XS1645687416

On July 5th 2017, Kedrion S.p.A. successfully completed the issuance of a 350 million euro senior, unsecured and unrated notes, which will be due July 2022. They are fixed-rate securities with a 3% coupon p.a.. Issue price is below par (99.43%). With a minimum denomination of 100,000 euros, such notes have been placed with leading international institutional investors and have been listed on the Irish Stock Exchange by the date of accrual, July 12th 2022.

Bond Quotes

XS1061608300 300mm eur Apr 2019

XS1645687416 350mm eur Jul 2022

For more information please contact: investor@kedrion.com